These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1199 related articles for article (PubMed ID: 29780381)

  • 1. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.
    Castro F; Cardoso AP; Gonçalves RM; Serre K; Oliveira MJ
    Front Immunol; 2018; 9():847. PubMed ID: 29780381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of IFN-γ in tumor progression and regression: a review.
    Jorgovanovic D; Song M; Wang L; Zhang Y
    Biomark Res; 2020; 8():49. PubMed ID: 33005420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The two faces of interferon-γ in cancer.
    Zaidi MR; Merlino G
    Clin Cancer Res; 2011 Oct; 17(19):6118-24. PubMed ID: 21705455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
    Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
    Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon gamma in cancer immunotherapy.
    Ni L; Lu J
    Cancer Med; 2018 Sep; 7(9):4509-4516. PubMed ID: 30039553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.
    Dillinger B; Ahmadi-Erber S; Lau M; Hoelzl MA; Erhart F; Juergens B; Fuchs D; Heitger A; Ladisch S; Dohnal AM
    Cell Immunol; 2018 Mar; 325():33-40. PubMed ID: 29402391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
    Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
    Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment.
    Lin W; Luo Y; Wu J; Zhang H; Jin G; Guo C; Zhou H; Liang H; Xu X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tumor growth by IFN-gamma in cancer immunotherapy.
    Beatty GL; Paterson Y
    Immunol Res; 2001; 24(2):201-10. PubMed ID: 11594457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion.
    Zhuang Q; Dai Z; Xu X; Bai S; Zhang Y; Zheng Y; Xing X; Hu E; Wang Y; Guo W; Zhao B; Zeng Y; Liu X
    Cancer Res; 2024 Feb; 84(3):405-418. PubMed ID: 37963197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The untold story of IFN-γ in cancer biology.
    Kursunel MA; Esendagli G
    Cytokine Growth Factor Rev; 2016 Oct; 31():73-81. PubMed ID: 27502919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects.
    Tagawa M; Kawamura K; Li Q; Tada Y; Hiroshima K; Shimada H
    Clin Dev Immunol; 2011; 2011():479013. PubMed ID: 22013482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
    Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
    Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis.
    Zheng H; Guan X; Meng X; Tong Y; Wang Y; Xie S; Guo L; Lu R
    J Ovarian Res; 2023 Nov; 16(1):229. PubMed ID: 38007483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy.
    Han J; Wu M; Liu Z
    Front Immunol; 2023; 14():1190333. PubMed ID: 37275859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.